Accessibility Menu
 
Spruce Biosciences logo

Spruce Biosciences

(NASDAQ) SPRB

Current Price$66.66
Market Cap$90.57M
Since IPO (2020)-95%
5 Year-94%
1 Year+198%
1 Month+5%

Spruce Biosciences Financials at a Glance

Market Cap

$90.57M

Revenue (TTM)

$0.00

Net Income (TTM)

$38.97M

EPS (TTM)

$-52.72

P/E Ratio

-1.25

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$66.66

Volume

0

Open

$64.60

Previous Close

$66.66

Daily Range

$63.40 - $68.46

52-Week Range

$4.28 - $240.00

SPRB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Spruce Biosciences

Industry

Biotechnology

Employees

8

CEO

Javier Szwarcberg, MD

Headquarters

Daly City, CA 94014, US

SPRB Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-109%

Return on Capital

-85%

Return on Assets

-73%

Earnings Yield

-80.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$90.57M

Shares Outstanding

1.37M

Volume

0

Short Interest

0.00%

Avg. Volume

42.61K

Financials (TTM)

Gross Profit

$21.00K

Operating Income

$36.51M

EBITDA

$36.51M

Operating Cash Flow

$33.33M

Capital Expenditure

$0.00

Free Cash Flow

$33.33M

Cash & ST Invst.

$48.91M

Total Debt

$736.00K

Spruce Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$5.00K

-100.7%

Gross Margin

0.00%

N/A

Market Cap

$90.57M

N/A

Market Cap/Employee

$4.53M

N/A

Employees

20

N/A

Net Income

$14.65M

+37.8%

EBITDA

$11.10M

+52.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$48.17M

+33.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$419.00K

-51.3%

Short Term Debt

$317.00K

-83.4%

Return on Assets

-73.49%

N/A

Return on Invested Capital

-85.04%

N/A

Free Cash Flow

$6.46M

+68.8%

Operating Cash Flow

$6.46M

+68.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VTVTvTv Therapeutics Inc.
$37.30-3.02%
EQEquillium, Inc.
$1.91+6.11%
OSTXOS Therapies Incorporated
$1.35+8.00%
COEPCoeptis Therapeutics, Inc.
$12.62+16.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$48.96+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.45+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$67.86-0.02%
CRWVCoreWeave
$92.00+0.03%

Questions About SPRB

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.